Search results for " Heart Failure"

showing 10 items of 154 documents

Changes in myocardial iron content following administration of intravenous iron (Myocardial‐IRON): Study design

2018

Treatment with intravenous ferric carboxymaltose (FCM) has been shown to improve symptoms, functional capacity, and quality of life in patients with heart failure and iron deficiency. However, the underlying mechanisms for these beneficial effects remain undetermined. The aim of this study is to quantify cardiac magnetic resonance changes in myocardial iron content after administration of intravenous FCM in patients with heart failure and iron deficiency and contrast them with parameters of heart failure severity. This is a multicenter, double-blind, randomized study. Fifty patients with stable symptomatic heart failure, left ventricular ejection fraction <50%, and iron deficiency will be r…

MaleTime FactorsMyocardial ironheart failure030204 cardiovascular system & hematologyFerric CompoundsSeverity of Illness IndexVentricular Function Left030218 nuclear medicine & medical imaginglaw.invention0302 clinical medicineiron deficiencyClinical ProtocolsQuality of lifeRandomized controlled triallawCardiac Magnetic Resonance Ferric Carboxymaltose Heart Failure Iron Deficiency Myocardial IronInfusions IntravenousEjection fractionAnemia Iron-DeficiencyGeneral MedicineIron deficiencyferric carboxymaltoseTreatment OutcomeResearch DesignCardiologyFemaleCardiology and Cardiovascular MedicineCardiac function curvemedicine.medical_specialtyTrial DesignsMagnetic Resonance Imaging CinePlacebocardiac magnetic resonance03 medical and health sciencesDouble-Blind MethodInternal medicinemedicineHumansMaltosemyocardial ironAgedHeart Failurebusiness.industryMyocardiumStroke VolumeRecovery of Functionmedicine.diseaseSpainHeart failureHematinicsQuality of Lifebusiness
researchProduct

Prognostic value of the interaction between galectin-3 and antigen carbohydrate 125 in acute heart failure

2015

AIM:Galectin-3 (Gal-3) and carbohydrate antigen 125 (CA125) have emerged as robust prognostic biomarkers in heart failure. Experimental data have also suggested a potential molecular interaction between CA125 and Gal-3; however, the biological and clinical relevance of this interaction is still uncertain. We sought to evaluate, in patients admitted for acute heart failure, the association between plasma Gal-3 with all-cause mortality and the risk for rehospitalizations among high and low levels of CA125. METHODS AND RESULTS: We included 264 consecutive patients admitted for acute heart failure to the Cardiology Department in a third-level center. Both biomarkers were measured on admission. …

Maleendocrine system diseasesGalectin 3lcsh:MedicineRisk FactorsBlood plasmaANTIGEN CARBOHYDRATE 125lcsh:ScienceAged 80 and overMultidisciplinaryca125Mortality rateBlood Proteins//purl.org/becyt/ford/3.1 [https]Middle AgedPrognosisMedicina BásicaGalectin-3Female//purl.org/becyt/ford/3 [https]Research Articlemedicine.medical_specialtyCIENCIAS MÉDICAS Y DE LA SALUDcontributesGalectinsInmunologíaPatient ReadmissionAntigenInternal medicinemedicineHumanssurfaceClinical significanceIn patientIntensive care medicineAgedProportional Hazards ModelsHeart FailureGALECTIN-3business.industryProportional hazards modellcsh:Rassociationmedicine.diseaseACUTE HEART FAILUREstatin therapyinflammationCA-125 AntigenHeart failurecellslcsh:QbusinessBiomarkersFollow-Up Studies
researchProduct

CA125-Guided Diuretic Treatment Versus Usual Care in Patients With Acute Heart Failure and Renal Dysfunction

2020

BACKGROUND: The optimal diuretic treatment strategy for patients with acute heart failure and renal dysfunction remains unclear. Plasma carbohydrate antigen 125 (CA125) is a surrogate of fluid overload and a potentially valuable tool for guiding decongestion therapy. The aim of this study was to determine if a CA125-guided diuretic strategy is superior to usual care in terms of short-term renal function in patients with acute heart failure and renal dysfunction at presentation. METHODS: This multicenter, open-label study randomized 160 patients with acute heart failure and renal dysfunction into 2 groups (1:1). Loop diuretics doses were established according to CA125 levels in the CA125-gui…

Maleendocrine system diseasesPREDICTIONmedicine.medical_treatmentUrine030204 cardiovascular system & hematologyKidney Function TestsCONGESTIONBiomarker guided-therapy0302 clinical medicineSodium Potassium Chloride Symporter InhibitorsFurosemideNatriuretic peptideMedicineRenal Insufficiency030212 general & internal medicinePrecision MedicineANTIGEN CARBOHYDRATE 125Aged 80 and overFurosemideGeneral MedicineDiuretic treatmentEUROPEAN-SOCIETYClinical trialFemaleTRIALmedicine.drugmedicine.medical_specialtyRenal failureSTRATEGIESmedicine.drug_classUrologyRenal function03 medical and health sciencesHumansIn patientAgedHeart FailureSERUM CREATININENATRIURETIC PEPTIDEbusiness.industryMORTALITYMembrane ProteinsAcute heart failuremedicine.diseaseClinical trialCarbohydrate antigen 125CA-125 AntigenHeart failureDiuretic treatmentDiureticbusinessCARDIORENAL SYNDROME
researchProduct

Refractory congestive heart failure: when the solution is outside the heart

2020

Abstract Refractory congestive heart failure is associated with an ominous prognosis in which the treatments strategies remain scarce and not well validated. In the last years, continuous ambulatory peritoneal dialysis (CAPD) has emerged as a therapeutic alternative in this subset of patients. So far, it has been associated with a significant improvement in functional capacity and quality of life, together with a striking reduction in the risk of readmissions. We present the case of an elderly patient with severe left ventricular dysfunction and severe mitral and tricuspid regurgitation who presents recurrent admissions for anasarca. After its inclusion in a CAPD programme, the patient expe…

Malelcsh:Diseases of the circulatory (Cardiovascular) systemmedicine.medical_specialtymedicine.medical_treatmentPeritoneal dialysisCase ReportRegurgitation (circulation)030204 cardiovascular system & hematologyAnasarcaVentricular Function LeftPeritoneal dialysis03 medical and health sciences0302 clinical medicinePeritoneal Dialysis Continuous AmbulatoryQuality of lifeRefractoryInternal medicinemedicineHumans030212 general & internal medicineAgedHeart Failurebusiness.industryContinuous ambulatory peritoneal dialysismedicine.diseaseTricuspid Valve InsufficiencyTreatmentRefractory congestive heart failureEchocardiographylcsh:RC666-701Heart failureQuality of LifeCardiologymedicine.symptomDiureticCardiology and Cardiovascular MedicinebusinessESC Heart Failure
researchProduct

Detectable interleukin-9 plasma levels are associated with impaired cardiopulmonary functional capacity and all-cause mortality in patients with chro…

2016

Inflammatory activation plays a pivotal role in chronic heart failure (CHF) through the increased expression of pro-inflammatory cytokines [1]. Decreased plasma levels of Interleukin (IL-) 5, IL-7 and Interferon-γ (IFN-γ) and increased levels of IL-9 have been already described in CHF [2], and a negative correlation was also reported between IL-9 and left ventricular ejection fraction (LVEF) [2]. Yet, there are only limited data exploring the association between cytokines and functional capacity in CHF and their prognostic role [3]; therefore, primary end-point of the current study was to evaluate all-cause mortality according to changes in cytokines plasma levels in CHF patients.  

Malemedicine.medical_specialty030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineCause of DeathmedicineHumansInterleukin 9030212 general & internal medicineInterleukin 6CytokineInterleukin 5Risk stratificationInterleukin 4OutcomeAgedHeart Failurebiologybusiness.industryRisk FactorInterleukin-9Middle Agedmedicine.diseaseChronic heart failurePeak oxygen consumptionInterleukin 10EndocrinologyInterleukin 15Heart failurebiology.proteinCardiologyFemaleChronic heart failure; Cytokines; Interleukin-9; Outcomes; Peak oxygen consumption; Risk stratification; Cardiology and Cardiovascular MedicineCardiology and Cardiovascular MedicinebusinessInterleukin 1 receptor type IHumanInternational journal of cardiology
researchProduct

Validity of the Seattle Heart Failure Model after heart failure hospitalization.

2019

Abstract Aims Heart failure hospitalization is a sentinel event associated with increased mortality risk. Whether long‐term heart failure risk models such as the Seattle Heart Failure Model (SHFM) accurately assess risk in the post‐hospital setting is unknown. Methods and results The SHFM was applied to a cohort of 2242 consecutive patients (50% women; mean age 73) on discharge after acute heart failure hospitalization and analysed for the primary endpoint of all‐cause mortality. Model discrimination and calibration were assessed. Direct patient‐level comparison between our study cohort and the original SHFM cohorts was also performed to confirm and quantify the degree and extent of increas…

Malemedicine.medical_specialty030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineRisk FactorsSeattle Heart Failure ModelInternal medicineOriginal Research ArticlesClinical endpointmedicineHumansIn patient030212 general & internal medicineOriginal Research ArticleHospital dischargeMortality riskAgedAged 80 and overHeart FailureModels StatisticalReceiver operating characteristicbusiness.industryReproducibility of ResultsAcute heart failureMean ageAfter dischargeMiddle Agedmedicine.diseaseHospitalizationHeart failureAmbulatoryCohortCardiologyFemaleCardiology and Cardiovascular MedicinebusinessESC heart failure
researchProduct

Low- vs high-dose ARNI effects on clinical status, exercise performance and cardiac function in real-life HFrEF patients.

2022

Purpose Only a few studies are available on dose-related effects of sacubitril/valsartan (angiotensin receptor neprilysin inhibition (ARNI)) in real-life patients with heart failure and reduced ejection fraction (HFrEF). We sought to investigate clinical and functional effects in real-life HFrEF patients receiving ARNI at a different cumulative dose. Methods This was an observational study in consecutive outpatients admitted for HFrEF from October 2017 to June 2019. The PARADIGM criteria were needed for enrolment. ARNI was uptitrated according to blood pressure, drug tolerability, renal function and kaliemia. At least 10-month follow-up was required in each patient. Clinical assessment, Kan…

Malemedicine.medical_specialtyARNIBlood PressureWalk TestComorbiditySacubitrilVentricular Function LeftAngiotensin Receptor AntagonistsInternal medicinemedicine6-min walking test Aged Aminobutyrates Angiotensin Receptor Antagonists ARNI Biphenyl Compounds Blood Pressure Comorbidity Dose-Response Relationship Drug Drug Combinations Echocardiography Female Heart failure Humans Left ventricular function Male Middle Aged Prospective Studies Sacubitril/valsartan Stroke Volume Valsartan Ventricular Function Left Walk TestHumansPharmacology (medical)Sacubitril/valsartanProspective Studies6-min walking testAgedPharmacologyHeart FailureEjection fractionDose-Response Relationship DrugCumulative dosebusiness.industryAminobutyratesLeft ventricular functionBiphenyl CompoundsStroke VolumeGeneral MedicineMiddle Agedmedicine.diseaseClinical TrialARNI heart failure left ventricular function 6-minutes walking test Sacubitril/valsartan.Drug CombinationsBlood pressureTolerabilityValsartanEchocardiographyHeart failureCardiologyValsartanFemalebusinessSacubitril Valsartanmedicine.drugEuropean journal of clinical pharmacology
researchProduct

Fluid therapy in non-septic, refractory acute decompensated heart failure patients – The cautious role of central venous pressure

2019

Purpose Fluid therapy in congestive acute decompensated heart failure (ADHF) patients might be inappropriate and worsening the prognosis. The aim of our study was to analyze the effect of fluid administration on mortality in non-septic, ADHF patients with reduced ejection fraction. Material and methods We analyzed 41 ADHF consecutive ‘cold-wet’ patients (mean age 69.3 ± 14.9 years, 27 men, LVEF 22.8 ± 11.1%, lactates 2.2 ± 1.6 mmol/L) without sepsis. At admission central venous pressure (CVP) was measured (17.6 ± 7.2 cm H2O), and ultrasound examination of inferior vena cava (IVC) was performed (IVC min. 18.6 ± 7.3 mm and IVC max. 24.6 ± 4.3 mm). Moreover, the groups were compared (survivors…

Malemedicine.medical_specialtyAcute decompensated heart failureKaplan-Meier EstimateInferior vena cavaStatistics NonparametricSepsisCentral venous pressure03 medical and health sciences0302 clinical medicineFluid therapyRefractoryFluid therapyInternal medicineSepsisMedicineHumans030212 general & internal medicineHospital MortalityAgedHeart FailureEjection fractionbusiness.industryCentral venous pressureAcute heart failureGeneral Medicinemedicine.diseasemedicine.veinQuartile030220 oncology & carcinogenesisCardiologyFemalebusinessAdvances in Medical Sciences
researchProduct

The Usefulness of Bioelectrical Impedance Analysis in Differentiating Dyspnea Due to Decompensated Heart Failure

2007

Acute dyspnea poses a diagnostic challenge for physicians, and the current methods in differentiating cardiac from non-cardiac causes have been limited to date. Recently, the brain natriuretic peptide (BNP) rapid test has been validated in the emergency room. Nevertheless, the early accumulation of fluid in the interstitial space in the body and in the lungs, which characterizes patients with ADHF, is well estimated by BIA. We investigate whether bioelectrical impedance analysis (BIA) can serve as a noninvasive diagnostic tool in the differential diagnosis of acute decompensated heart failure (ADHF) in the emergency department (ED).A total of 292 patients presenting with acute dyspnea to th…

Malemedicine.medical_specialtyAcute decompensated heart failuremedicine.drug_classSensitivity and SpecificityDiagnosis DifferentialInternal medicineNatriuretic Peptide BrainElectric ImpedancemedicineNatriuretic peptideHospital dischargeHumansIntensive care medicineAgedHeart Failurebusiness.industryEmergency departmentMiddle Agedmedicine.diseaseBrain natriuretic peptideDyspneaROC CurveHeart failureCardiologyFemaleDifferential diagnosisCardiology and Cardiovascular MedicinebusinessBioelectrical impedance analysisAlgorithmsJournal of Cardiac Failure
researchProduct

The glucocorticoid in acute decompensated heart failure: Dr Jekyll or Mr Hyde?

2012

Glucocorticoid administration is not recommended in patients with heart failure because of its related sodium and fluid retention. However, previous experimental and clinical studies have demonstrated that glucocorticoids can also induce a diuretic effect and improve renal function in patients with acute decompensated heart failure (ADHF) with refractory diuretic resistance. We report the case of a 65-year-old man with a known diagnosis of aortic stenosis, systolic ventricular dysfunction, and chronic obstructive pulmonary disease who was admitted for ADHF. After 3 days, during which resistance to conventional therapy was observed, intravenous methylprednisolone (60 mg/d) was added to ongoi…

Malemedicine.medical_specialtyAcute decompensated heart failuremedicine.medical_treatmentRenal functionMethylprednisoloneRefractoryInternal medicinemedicineHumansDiureticsGlucocorticoidsAgedHeart Failurebusiness.industryGeneral Medicinemedicine.diseaseBrain natriuretic peptideStenosisglucocorticoid. acute decompensated hert failureEndocrinologyHeart failureAcute DiseaseEmergency MedicineCardiologyDiureticbusinessGlucocorticoidmedicine.drug
researchProduct